Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.96 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.48 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11440530 | 0.85 | LMNA (0.71) | LMNAHPGDALDH1A1TSHRPOLB | |
| SCHEMBL11578854 | 0.84 | LMNA (0.70) | LMNAHPGDALDH1A1TSHRPOLB | |
| SCHEMBL2092062 | 0.83 | LMNA (0.69) | LMNAHPGDALDH1A1TSHRPOLB | |
| SCHEMBL27478662 | 0.82 | LMNA (0.68) | LMNAHPGDALDH1A1TSHRPOLB | |
| SCHEMBL12883186 | 0.82 | TSHR (0.77) | LMNAHPGDALDH1A1TSHRPOLB | |
| SCHEMBL2092059 | 0.82 | LMNA (0.67) | LMNAHPGDALDH1A1TSHRPOLB | |
| SCHEMBL4214095 | 0.80 | LMNA (0.65) | LMNAHPGDALDH1A1TSHRPOLB | |
| Glycinexylidide SCHEMBL4107220 | 0.80 | LMNA (0.65) | LMNAALDH1A1POLBMEN1KMT2A | |
| SCHEMBL3952909 | 0.80 | ALDH1A1 (0.68) | LMNAHPGDALDH1A1TSHRPOLB | |
| SCHEMBL10333606 | 0.78 | POLB (0.64) | LMNAHPGDALDH1A1TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090226422-A1 | Chemical Inhibitors of Inhibitors of Differentiation | ANGIOGENEX | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226422-A1 | Chemical Inhibitors of Inhibitors of Differentiation | BRAF, MAPK1, RAF1 | LMNA 2937/4885HPGD 3243/4885ALDH1A1 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.